Mentis Care, an AI-driven neuromonitoring company, announced a two-year research collaboration with Emory University’s School of Medicine to develop channel-agnostic AI models for seizure detection and real-time prediction.
The initiative centers on building a transformer-based EEG foundation model capable of operating across a wide range of EEG configurations, from traditional clinical systems to reduced-channel wearable devices. The goal is to enable continuous, real-world monitoring for epilepsy patients, addressing longstanding limitations tied to complex EEG setups and inconsistent signal quality.
Epilepsy affects more than 50 million people globally, with roughly one in three patients unable to fully control seizures through existing therapies. Current monitoring approaches are largely confined to clinical environments, resulting in episodic data collection rather than continuous insights into patient conditions.
Mentis Care’s approach aims to overcome these challenges by developing AI models that can filter noise, adapt across different electrode configurations, and potentially predict seizures in advance. The company is targeting at least five minutes of preictal forecasting, which could significantly improve patient safety and independence.
The research program will leverage more than one million hours of de-identified EEG data from Emory Healthcare and will focus on five key areas:
- Large-scale data curation and standardized preprocessing pipelines
- Development of a high-performance seizure detection foundation model
- Validation across diverse patient populations and environments
- Adaptation to reduced-channel wearable EEG systems
- Extension into real-time seizure prediction capabilities
Mentis Care’s engineering team will work closely with Emory researchers on model architecture, validation, and system integration, with an emphasis on commercial deployment readiness. The agreement also includes provisions for potential licensing of resulting technologies.
The research remains at an early stage, and any future product will require further development, clinical validation, and regulatory approval before reaching patients.
Mentis Care is developing its platform as a Software as a Medical Device (SaMD) and is pursuing FDA clearance. The company is a joint venture between SK Biopharmaceuticals and Eurofarma.
KEY QUOTES:
“We are on a mission to transform epilepsy care: to shorten the years patients spend cycling through treatments and to reduce the number who never achieve stability. Channel-agnostic AI is not a feature; it is the foundation that makes continuous, real-world monitoring possible for the first time. For the one in three people whose seizures remain uncontrolled, that changes everything.”
Hassan Kotob, CEO, Mentis Care
“Foundation models are redefining what’s possible in healthcare, and nowhere is that more apparent than in seizure detection. By adapting across channel configurations, they enable high-performance detection even in reduced-channel wearable formats, bringing clinical-grade monitoring closer to everyday life. We were among the first to pursue this direction, and our focus remains the same: closing the gap between research and clinical reality. This collaboration is a cornerstone for unlocking EEG at scale and advancing a broader understanding of brain function that benefits all of medicine.”
Dr. Samaneh Nasiri, Principal Investigator, Emory University School of Medicine; Advisory Role, Mentis Care
“The eye may be the window into the brain, but the EEG is the brain’s stethoscope that listens to its electrical conversations … and not just for epilepsy, but for sleep, memory, movement disorders, and many other neurological conditions we are only beginning to understand. This research collaboration will accelerate our analysis of EEG at scale and will bring us closer to a broader understanding of brain function that will benefit a broad range of diseases.”
Dr. Gari Clifford, Chair, Department of Biomedical Informatics; Professor of Biomedical Informatics and Biomedical Engineering, Emory University & Georgia Institute of Technology
“Beyond innovative medicines, SK Biopharmaceuticals is exploring new possibilities in patient treatment through AI-based digital healthcare. Through Mentis Care, we will continue to advance patient-centered therapeutic innovation by integrating AI technologies.”
Donghoon Lee, President & CEO, SK Biopharmaceuticals and Its U.S. Subsidiaries
